Many predicted that all men at high risk of the disease were likely to be included in new screening plans.
But the committee stopped short of that recommendation.
Despite black men having twice the risk of prostate cancer, it said there should be no screening for black men due to “uncertainties” around its impact, and a lack of evidence from clinical trials in these men.
It also recommended no screening for men with a family history of the disease, for the same reason – too many cancers would be overdiagnosed and overtreated.
But men with specific genetic mutations – called BRCA variants – develop faster-growing and aggressive cancers at an earlier age, making screening for them justified.
Treating these cancers earlier is more likely to benefit those men and outweigh the potential harm from unnecessary treatment, compared to men in the general population, the experts said.